[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)].
This article reviews the theoretical background, the sometimes severe side effects and the possible clinical implications of treatments with monoclonal anti-T cell antibodies in Multiple Sclerosis (MS). We conclude that there is no indication for treatment with monoclonal anti-T cell antibodies at the present time, except in controlled trials.
Schmidt
S
S
Abteilung Neuroimmunologie, Max Planck-Institut für Psychiatrie, Martinsried.
Hohlfeld
R
R
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm; D017252:CD3 Complex / Q000276:immunology*; D015704:CD4 Antigens / Q000276:immunology*; D000074301:CD52 Antigen; D002986:Clinical Trials as Topic; D006023:Glycoproteins; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D051381:Rats; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D017252:CD3 Complex; D015704:CD4 Antigens; D000074301:CD52 Antigen; C000613862:CD52 protein, human; C000613864:Cd52 protein, rat; D006023:Glycoproteins